Goldman Sachs Secures Veteran Equity Research Analyst Graig Suvannavejh

Goldman Sachs has made another big hire, this time securing Graig Suvannavejh as an executive director and Senior equity research analyst. In particular, Suvannavejh will be following the European biotechnology sector.

The addition of Suvannavejh comes at a time when the American multinational investment bank is bolstering its research team. This is in reaction to the new regulatory framework in the European Union (EU) thanks to MiFID II.

Under the new Regulation Regulation Like any other industry with a high net worth, the financial services industry is tightly regulated to help curb illicit behavior and manipulation. Each asset class has its own set of protocols put in place to combat their respective forms of abuse.In the foreign exchange space, regulation is assumed by authorities in multiple jurisdictions, though ultimately lacking a binding international order. Who are the Industry’s Leading Regulators?Regulators such as the UK’s Financial Conduct Authority ( Like any other industry with a high net worth, the financial services industry is tightly regulated to help curb illicit behavior and manipulation. Each asset class has its own set of protocols put in place to combat their respective forms of abuse.In the foreign exchange space, regulation is assumed by authorities in multiple jurisdictions, though ultimately lacking a binding international order. Who are the Industry’s Leading Regulators?Regulators such as the UK’s Financial Conduct Authority ( Read this Term, big investment banks are seeking senior research specialists in the hope it will increase revenues. Suvannavejh fits the model to a tee, as he has extensive experience as an equity research analyst, with a focus on biotechnology and pharmaceuticals. He joined the firm earlier this month and is based in its London office.

Graig Suvannavejh's Experience Before Goldman Sachs

Before working at Goldman Sachs, Suvannavejh has worked at a number of big-name investment banks. In 2000, he began his career as an analyst at JPMorgan. In addition, he has held the position of Director at UBS, Vice President at global investment banking firm Jefferies and was also employed by CIBC Capital Markets.

Most recently, Suvannavejh was the Business Development lead for AbbVie's Global Commercial Development group. AbbVie is a pharmaceutical research and development company. In the role, he focused on specialty products. According to his LinkedIn, this included Neuroscience, Hepatology, Women's Health, among others. He joined the company in March last year and worked there until July 2018.

Before that, between April 2016 up until February 2017, Suvannavejh worked in Corporate Development and Investor Relations at Alzheon, Inc., an Alzheimer research clinic. In this role, he helped with the revision of the company’s overall financial and clinical strategies. He also helped to maintain and expand relationships with Buy-Side Buy-Side The buy-side is comprised of firms in the financial industry that purchase securities and are accompanied by account investment managers, pension funds, and hedge funds.The buy-side is composed of those that buy and invest large sums of securities with the intention of generating a lucrative return or have their funds managed. The Buy-Side ExplainedIn terms of Wall Street, the buy-side includes investment institutions that purchase securities, stocks, or other financial instruments with the aim The buy-side is comprised of firms in the financial industry that purchase securities and are accompanied by account investment managers, pension funds, and hedge funds.The buy-side is composed of those that buy and invest large sums of securities with the intention of generating a lucrative return or have their funds managed. The Buy-Side ExplainedIn terms of Wall Street, the buy-side includes investment institutions that purchase securities, stocks, or other financial instruments with the aim Read this Term institutional investors, sell-side biotechnology analysts, and investment bankers.

Throughout his career, Suvannavejh has also worked as an Associate Director at Biogen Idec, Senior Analyst at MLV & Co. and a Managing Partner at Axon Healthcare Partners. Between 1988 to 1993, he studied at Georgetown University. In 1992 he graduated with a Bachelor of Science in Biology and in 1993, he completed his Master of Science for Biology. Suvannavejh then went on to earn a Ph.D. in Neuroscience from Northwestern University, graduating with the qualification in 2000.